ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma

Sheybani, Natasha D.; Breza, Victoria R.; Paul, Soumen; McCauley, Katelyenn S.; Berr, Stuart S.; Miller, G. Wilson; Neumann, Kiel D.; Price, Richard J.

doi:10.1016/j.jconrel.2021.01.023

Cited by 35 publications

(18 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, several immuno-PET imaging tracers have been designed to target glioblastoma and have already proven successful in detecting gliomas in multiple preclinical models. These tracers target membrane proteins whose expression is altered in glioblastoma (including the EGFR, DLL4, EPHA2, CD47, AC133 antigen, and MT1-MMP) [ 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 106 , 107 ]: several components of the tumor microenvironment including vessels, macrophages, and extracellular matrix proteins [ 104 , 105 , 108 , 109 , 110 , 114 ]. Notably, [ 89 Zr]Zr-DFO-fresolimumab, an immuno-PET tracer based on a monoclonal antibody that can neutralize all mammalian isoforms of TGF-β was assayed in humans, penetrated recurrent high-grade gliomas but did not result in clinical benefit [ 109 ].…”

Section: Discussionmentioning

confidence: 99%

“…These tracers allow for evaluating multiple hallmarks [29] of gliomas and the treatment response in preclinical settings. Several immuno-PET tracers' [94][95][96][97][98][99][100][101]106,107] target membrane proteins whose expression is altered in glioblastoma including the Epidermal Growth Factor Receptor (EGFR), Delta-Like Ligand 4 (DLL4), Ephrin type-A receptor 2 (EPHA2), Cluster of differentiation 47 (CD47), the AC133 antigen, and the Membrane-type 1 matrix metalloproteinase (MT1-MMP/MMP14) (Figure 5). In vivo administration of these tracers showed high-specificcontrast imaging of the target in an MT1-MMP expressing glioblastoma tumor model and provided strong evidence for their utility as an alternative to non-specific imaging of glioblastoma.…”

Section: Current Perspectives Of Immuno-pet For Glioblastomamentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography

Ruiz-López

Calatayud-Pérez

Castells-Yus

et al. 2021

Cancers

View full text Add to dashboard Cite

Neuroimaging has transformed neuro-oncology and the way that glioblastoma is diagnosed and treated. Magnetic Resonance Imaging (MRI) is the most widely used non-invasive technique in the primary diagnosis of glioblastoma. Although MRI provides very powerful anatomical information, it has proven to be of limited value for diagnosing glioblastomas in some situations. The final diagnosis requires a brain biopsy that may not depict the high intratumoral heterogeneity present in this tumor type. The revolution in “cancer-omics” is transforming the molecular classification of gliomas. However, many of the clinically relevant alterations revealed by these studies have not yet been integrated into the clinical management of patients, in part due to the lack of non-invasive biomarker-based imaging tools. An innovative option for biomarker identification in vivo is termed “immunotargeted imaging”. By merging the high target specificity of antibodies with the high spatial resolution, sensitivity, and quantitative capabilities of positron emission tomography (PET), “Immuno-PET” allows us to conduct the non-invasive diagnosis and monitoring of patients over time using antibody-based probes as an in vivo, integrated, quantifiable, 3D, full-body “immunohistochemistry” in patients. This review provides the state of the art of immuno-PET applications and future perspectives on this imaging approach for glioblastoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Current Perspectives Of Immuno-pet For Glioblastomamentioning

confidence: 99%

Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography

Ruiz-López

Calatayud-Pérez

Castells-Yus

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…In this regard, novel cyclic peptides modulating the BBB enhanced the brain delivery of mAbs [ 196 ]. Similarly, focused ultrasound-mediated BBB disruption improved anti-CD47 mAbs delivery to GBM tumors [ 199 ].…”

Section: Limitations Of Current Preclinical Models and Future Outlook To Improve Combination Strategies For The Immunotherapy Of Gbmmentioning

confidence: 99%

Immunotherapy for glioblastoma: the promise of combination strategies

Bausart

Préat

Malfanti

2022

J Exp Clin Cancer Res

129

View full text Add to dashboard Cite

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The current standard of care involves surgical resection (if possible) followed by concomitant radiotherapy and chemotherapy. In recent years, immunotherapy strategies have revolutionized the treatment of many cancers, increasing the hope for GBM therapy. However, mostly due to the high, multifactorial immunosuppression occurring in the microenvironment, the poor knowledge of the neuroimmune system and the presence of the blood−brain barrier, the efficacy of immunotherapy in GBM is still low. Recently, new strategies for GBM treatments have employed immunotherapy combinations and have provided encouraging results in both preclinical and clinical studies. The lessons learned from clinical trials highlight the importance of tackling different arms of immunity. In this review, we aim to summarize the preclinical evidence regarding combination immunotherapy in terms of immune and survival benefits for GBM management. The outcomes of recent studies assessing the combination of different classes of immunotherapeutic agents (e.g., immune checkpoint blockade and vaccines) will be discussed. Finally, future strategies to ameliorate the efficacy of immunotherapy and facilitate clinical translation will be provided to address the unmet medical needs of GBM.

show abstract

“…In addition, brain-focused ultrasound was found to downregulate the efflux transporter, P-glycoprotein, in the targeted brain regions (H. Cho et al, 2016 ). Since 2004, when Sheikov and his colleagues demonstrated for the first time that brain-focused ultrasound allowed BBB permeabilization to molecules as large as IgG ( Sheikov, McDannold, Vykhodtseva, Jolesz, & Hynynen, 2004 ), there has been several studies demonstrating the relevance of brain-focused ultrasound to improve the delivery of systematically administered antibody into specific brain areas, particularly in tumours and Alzheimer’s disease ( Dubey et al, 2020 ; Janowicz, Leinenga, Gotz, & Nisbet, 2019 ; Jordao et al, 2010 ; Kinoshita, McDannold, Jolesz, & Hynynen, 2006 ; Kobus, Zervantonakis, Zhang, & McDannold, 2016 ; Leinenga, Bodea, Koh, Nisbet, & Gotz, 2020 ; Liu et al, 2016 ; Park, Zhang, Vykhodtseva, & McDannold, 2012 ; Raymond et al, 2008 ; Sheybani et al, 2021 ). Overall, brain-focused ultrasound seems to be a promising technique to deliver antibody to targeted areas in the CNS, but the secondary effects of this technique on the brain still need to be further assessed ( Todd et al, 2020 ).…”

Section: Fcrn and Cellular Barriersmentioning

confidence: 99%

Therapeutic antibodies – natural and pathological barriers and strategies to overcome them

Ojaimi

Blin

Lamamy

et al. 2022

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Antibody-based therapeutics have become a major class of therapeutics with over 120 recombinant antibodies approved or under review in the EU or US. This therapeutic class has experienced a remarkable expansion with an expected acceleration in 2021–2022 due to the extraordinary global response to SARS-CoV2 pandemic and the public disclosure of over a hundred anti-SARS-CoV2 antibodies. Mainly delivered intravenously, alternative delivery routes have emerged to improve antibody therapeutic index and patient comfort. A major hurdle for antibody delivery and efficacy as well as the development of alternative administration routes, is to understand the different natural and pathological barriers that antibodies face as soon as they enter the body up to the moment they bind to their target antigen. In this review, we discuss the well-known and more under-investigated extracellular and cellular barriers faced by antibodies. We also discuss some of the strategies developed in the recent years to overcome these barriers and increase antibody delivery to its site of action. A better understanding of the biological barriers that antibodies have to face will allow the optimization of antibody delivery near its target. This opens the way to the development of improved therapy with less systemic side effects and increased patients’ adherence to the treatment.

show abstract

ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma

Cited by 35 publications

References 60 publications

Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography

Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography

Immunotherapy for glioblastoma: the promise of combination strategies

Therapeutic antibodies – natural and pathological barriers and strategies to overcome them

Contact Info

Product

Resources

About